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Abstract: The aim of this analysis was to assess the early clinical results of pencil beam scanning proton
therapy (PT) in the treatment of young children with non-metastatic atypical teratoid/rhabdoid tumor
(ATRT) of the CNS. Fifteen children (male, n = 8, 53 %) were treated with PT between May 2008 and
January 2013. Mean age at diagnosis was 17.4 ± 7.0 months. The localization was infratentorial in 9
(60 %) patients. Gross total resection of the primary tumors was achieved in 7 (47 %) patients. The
dose administered focally under sedation was 54 Gy (RBE). After a median follow-up of 33.4 months
(range 9.7-69.2), 3 (20 %), 4 (27 %) and 2 (13 %) patients presented with local failure (LF), distant
brain failure (DBF) and spinal failure (SF), respectively. Six patients died, all of tumor progression.
The 2-year overall- and progression-free survival was 64.6 and 66.0 %. Tumor location (supratentorial)
and the extent of surgical resection (non-gross total resection) were negative prognostic factors for both
OS and PFS. PT was well tolerated. No grade >2 acute toxicity was observed. The estimated 2-year
toxicity-free survival was 90 %. As assessed by the PedsQoL proxy, no decrease in QoL was observed after
PT. We conclude that PBS PT is an effective treatment for young children with ATRT. After PT, with
or without concomitant chemotherapy, two third of the patients survived >2 years. Acute toxicity was
manageable. Longer follow-up and larger numbers of patients are needed to assess long-term outcomes
and treatment-induced toxicity.
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Abstract The aim of this analysis was to assess the early
clinical results of pencil beam scanning proton therapy
(PT) in the treatment of young children with non-metastatic
atypical teratoid/rhabdoid tumor (ATRT) of the CNS.
Fifteen children (male, n = 8, 53 %) were treated with PT
between May 2008 and January 2013. Mean age at diag-
nosis was 17.4 ± 7.0 months. The localization was infra-
tentorial in 9 (60 %) patients. Gross total resection of the
primary tumors was achieved in 7 (47 %) patients. The
dose administered focally under sedation was 54 Gy
(RBE). After a median follow-up of 33.4 months (range
9.7–69.2), 3 (20 %), 4 (27 %) and 2 (13 %) patients pre-
sented with local failure (LF), distant brain failure (DBF)
and spinal failure (SF), respectively. Six patients died, all
of tumor progression. The 2-year overall- and progression-
free survival was 64.6 and 66.0 %. Tumor location
(supratentorial) and the extent of surgical resection (non-
gross total resection) were negative prognostic factors for
both OS and PFS. PT was well tolerated. No grade[2
acute toxicity was observed. The estimated 2-year toxicity-
free survival was 90 %. As assessed by the PedsQoL
proxy, no decrease in QoL was observed after PT. We
conclude that PBS PT is an effective treatment for young
children with ATRT. After PT, with or without concomi-
tant chemotherapy, two third of the patients survived
[2 years. Acute toxicity was manageable. Longer follow-
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up and larger numbers of patients are needed to assess
long-term outcomes and treatment-induced toxicity.
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Introduction
Atypical teratoid/rhabdoid tumor (ATRT) of the CNS is a
rare, highly malignant and extremely aggressive embryonal
neoplasm of early childhood. This tumor accounts for
1–2 % of CNS pediatric tumors but up to 20 % of malig-
nant CNS neoplasms in patients younger than 3 years of
age [1–3]. Administered treatments are not ATRT specific
and are highly variable but typically includes multi-
modality treatment, namely surgery, chemotherapy and
radiation therapy (RT). After this multimodality strategy,
most patients suffer swift disease recurrence and death
owing to tumor-progression. The mean reported survival
time of these young ATRT children ranges from 6 to
?18 months [4]. It is thus of paramount importance to
improve tumor control and/or decrease treatment-related
toxicity for these young patients.
Technical improvements in radiation therapy may
improve the therapeutic ratio for these challenging patients.
Unlike conventional radiotherapy, proton therapy (PT)
allows for optimal dose distributions, with the added ben-
efit of no exit dose. This absence of exit dose has triggered
the rational of using protons for children with various
cancer types. In a simulation study, the risk of adverse
effect in pediatric patients with medulloblastoma was
estimated to be the lowest with PT, when compared to
photon, with or without intensity modulation, plans [5].
The physical, emotional and social aspects of the child’s
well-being is of prime importance for these patients, as cancer
and its associated treatments are stressful and reduce the
Quality of life (QoL) in children. As such, there is a need for
health professionals to fully assess the treatment-impact of the
multi-modality therapy administered to these young children.
We assessed the clinical results, not limited but including
the recurrence pattern, toxicity and QoL, of pencil beam
scanning (PBS) PT in the treatment of non-metastatic ATRT
patients treated at the Paul Scherrer Institute (PSI).
Methods and materials
Patients
Between May 2008 and January 2013, 15 consecutive
children with non-metastatic ATRT aged from 4.6 to 27.4
(median 18.9) months were treated with PBS PT at PSI.
Eighty seven percent of these patients were\24 months old
and 20 %\12 months of age. There were seven girls and
eight boys. The majority (n = 12; 80 %) of tumors were
\5 cm. Original immunohistochemistry investigations
varied in scope (Table 1). All tested tumors presented with
nuclear loss of INI-1 (Table 1). In nine children, ATRTs
were located in the posterior fossa. Gross total resection was
defined as gross macroscopic removal of the visible tumor,
as defined by the surgeon’s operative notes and the absence
of tumor on the postoperative imaging studies. Subtotal
resection and macroscopic complete resection was per-
formed in seven patients each. All patients underwent
postoperative MRI. Second look surgery after chemother-
apy, decided by a multi-disciplinary team assessing the
tumor response, was performed in 3 (20 %) patients and
another of these patients became tumor-free. Eight (53 %)
patients had thus no residual disease before PT.
All patients received varied forms of chemotherapy (See
Table 2 for details). Legal representatives gave consent for
patients.
PT planning and delivery
All patients were immobilized using a combination of body
cast and a vacuum-assisted bite-block system (Supraten-
torial ATRT) or thermoplastic mask (Infratentorial ATRT).
Patient positioning was checked before every fraction, as
published previously [6]. The GTV was defined as the
macroscopic tumor identified on the brain magnetic reso-
nance imaging (MRI) performed before the initiation of
chemotherapy and PT, the residual tumor, if any, identified
on the pre-PT brain MRI scan and the tumor bed identified
on the planning computed tomography (CT) scan during
simulation. The clinical target volume (CTV) included the
GTV plus a 10 mm margin extension modified anatomi-
cally for microscopic involvement. The planning target
volume (PTV) encompassed the CTV plus a 5-mm margin.
The median planning target volume was 117.3 cc (range
35.0–202.0).
The relative biologic effectiveness (RBE) factor for
protons of 1.1 (relative to that of 60Co) was used, and
proton doses were expressed in terms of Gy(RBE)
[Gy(RBE) = proton Gy 9 1.1] (ref). All patients received
54 Gy(RBE) in 30 fractions of 1.8 Gy(RBE). Patients were
treated using the spot-scanning technique at the scanning
gantry by using the 250- MeV medical dedicated cyclotron.
Proton dose was computed using a 3-dimensional dose
calculation algorithm developed at PSI [7]. Single-field
uniform dose (SFUD) plans and IM proton therapy (IMPT)
plans were used sequentially at PSI.
Dose constraints to organs at risk (OARs) were deter-
mined as maximum dose (D2) of 50 and 54 Gy(RBE) to
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the center and surface of the brainstem or spinal cord,
50 Gy(RBE) to the optic chiasm, 45 Gy(RBE) to the optic
nerves, mean/maximum dose (D2) of 20/30 Gy(RBE) to
the lacrimal glands, mean/maximum dose (D2) of
36/45 Gy(RBE) to the cochlea’s and mean/maximum dose
(D2) of 7/10 Gy(RBE) to the lens.
PT was administered 7.2 (range 2.0–14.5) and 3.8 (range
0.6–8.0) months after the diagnosis and last surgery,
respectively. Focal (i.e. non-craniospinal irradiation) only
PT was delivered to all patients. Treatment plans were
optimized to maximize the coverage of the GTV while
observing OAR dose constraints. An example of a treat-
ment plan for an ATRT is given in Fig. 1.
PT was delivered in 38 to 43 (median 42) days, with a
2–3 series plan, using single field uniformed dose and
intensity modulated PT.
Quality of life
We investigated health-related QoL in all patients treated
with PT for ATRT. Instruments included a questionnaire
on life situations, PedsQoL proxy (parents’ questionnaire
for parents with children aged B4 years) [8]. Parents
answered a multidimensional questionnaire on child’s
autonomy and cognitive or behavioral difficulties and on
the socio-psychological impact of the illness on their own
everyday life. Higher PedsQoL proxy scores suggest better
patients’ QoL. The sample included all patients (n = 15)
who had been enrolled into the multinational, multicenter
prospective surveillance study of children with cancer led
by the University of Münster. QoL evaluations (Table 3)
were made at baseline (E1) before PT and 2 months after
the end of PT (E2), so as to assess the impact of PT on
QoL.
Follow-up
We used the RECIST classification to assess the radiologic
outcome (partial response [PR], C30 % decrease in maxi-
mum diameter), stable disease (SD\ 30 % decrease and
\20 % increase in maximum diameter), and progressive
disease (PD C 20 % increase in maximum diameter).
Complete response (CR) was defined as the complete dis-
appearance of the ATRT. Radiologic criteria for tumor
progression, locally, distant brain and spinal, were defined
as tumor growth or tumor recurrence in two consecutive
MRI or CT scans. Acute toxicities were defined as those
adverse events that occur from the first day of treatment
through day 90 after treatment. All side effects observed
after 90 days from the end of PT were considered as late
adverse events. These were classified according to the
National Cancer Institute Common Terminology Criteria




Overall (OS), progression-free (PFS) and late toxicity-free
(TFS) survival times were determined from the date of the
diagnosis. Survival rates were calculated using the actuarial
method of Kaplan–Meier. Observations were censored on
Table 1 Immunohistochemistry results and proliferative indexes of 15 ATRT children treated with proton therapy
Study number Vimentin GFAP EMA Synaptophysin Desmin INI-1 MAP-2 NSE NeuN S100 p53 MIB1 (%)
1 NP NP ? - NP Loss NP NP NP - NP NP
2 ?? NP ? - - Loss ? NP NP - NP 20
3 ?? ? NP ? NP Loss NP NP NP NP ? 80
4 ?? ? ? - - Loss ? NP - NP ± 10
5 ?? ? - NP NP Loss ? NP NP ? ? NP
6 ?? ? ? ? - Loss ? NP NP ? ? 50
7 NP ? ? - NP Loss ? ? ? NP NP 20
8 ?? ? NP ? NP Loss NP NP NP NP ? 50
9 NP ± ± ? NP Loss ? ? NP ± NP 40
10 NP - ? ? NP Loss ? - NP ? NP 20
11 ?? - ? NP NP Loss NP ? - NP NP NP
12 ?? ? ? - - Loss NP NP NP NP NP 30
13 ?? ? NP NP NP Loss ? NP NP NP NP 10
14 NP ? ? ? NP Loss NP NP NP ? NP 50
15 ?? - ? - - Loss - NP ? NP ? 10
NP not performed, ±\10 % expression, ? focal expression, ?? strong expression, - negative
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death or end of follow-up for survival and tumor control
endpoints. v2 test, or the Fischer exact test when appro-
priate, was used to assess differences in patient distribution
between groups. To assess variables influencing tumor
control and OS and PFS, univariate analyses (using the log-
rank statistics at the 0.05 a level) were performed to
evaluate clinical (gender, age, tumor location, tumor size)
and therapeutic (type of surgery, concomitant chemother-
apy) factors. All p values were based on a 2-sided
hypothesis. The statistical analyses were performed on the
SPSS statistics program, version 22 (IBM Corporation,
Armonk, New York, USA).
Results
Of those patients with residual disease before PT (n = 7), 2
(28.2 %) patients achieved complete response,
11.4–13.8 months after PBS. Three (43.0 %) patients had sta-
ble disease (mean diameter decrease, 7.0 %; range 0.9–13.0)
after irradiation and two other (28.5 %) patients presented with
PD, exhibiting a significant increase in tumor diameter
(increase of ?48.9 and ?57.1 %, respectively). No pseudo-
progression was observed.
After a median follow-up of 33.4 months (range
9.7–69.2) for all patients and 37.1 months (range
17.8–69.2) for living patients, 6 patients have experienced
tumor recurrence or progression. The estimated 2-year PFS
was 66.0 % (CI 95 % 41.7–90.3). Three patients with
supratentorial tumors (p = 0.04) presented with a local
failure (LF), 8.7–18.4 (median, 10.7) months after PT
(Table 2). The estimated 2-year LF-free survival was
78.0 % (CI 95 % 55.7–100). Four other patients presented
with distant brain failure (DBF), 1.3–28.5 (median 7.1)
months after PT. The estimated 2-year DBF-free survival
was 76.6 % (CI 95 % 43.9–100). These failures were
Fig. 1 Dose distribution of a treatment plan superimposed on CT
images of a patient with an supratentorial ATRT, a coronal, b sagital
and c coronal views. Note the rapid dose decline between the target
and non-target volumes and the optional sparing of contro-lateral
brain (coronal and axial slices). The isodose contours are represented
by the color-wash (corresponding values are displayed on the right
border of the figure)










































62.50 [±8.33] (4) 43.71 [±15.43] (7) 42.01 [±17.84]
(7)
Bold values are the mean of all scores for the various sub-scores
SD Standard deviation
a Baseline, prior to PT
b approximately, 2 months after the completion of all therapy
c Number of E1 evaluation do not add to n = 15, as not all proxy filled all domains
d Number of E2 evaluation do not add to n = 9, as not all proxy filled all domains
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observed in the ponto-cerebellar angle in 2 patients and
another two patients presented with brain leptomeningeal
recurrences. All four DBFs occurred in patients with AT-
RTs in supratentorial location (p = 0.01). Spinal failures
were observed in 2 patients (infratentorial: n = 1; supra-
tentorial: n = 1), 12.3 and 37.1 months after PT (Table 2).
The estimated 2-year spinal PFS was 92.9 % (CI 95 %
79.4–100). Combined treatment failures (LF and DBF,
n = 2; DBF and SF, n = 1) were observed in 3 patients.
Salvage ‘curative’ therapy was administered to 2 (33 %)
patients and best supportive care was proposed to another 4
(67 %) patients (Table 2). For the former patients, surgery
and chemotherapy was administered to one patient and
surgery, PT (second irradiation) and chemotherapy was
administered to the other patient. These two patients sur-
vived 23.5 and 59.3 months, respectively.
Six deaths were caused by LF, DBF or SF (Table 2).
The estimated 2-year OS was 64.6 % (CI 95 % 39.3–89.9).
On univariate analysis, tumor location was statistically
significant for both OS and PFS (Fig. 2). The 2-year OS
and PFS for infra- and supratentorial ATRTs were both
88.9 and 33.3 %, respectively (OS: p = 0.012; PFS:
p = 0.013). The latter localization was observed usually in
younger patients. Sixty seven percent and 33 % of patients
\12 months presented with a supra- and infratentorial
ATRT, respectively (p = 0.53). There was a statistical
trend toward significance for the type of surgical resection.
The 2-year OS for patients with a complete resection and
those with a subtotal resection/biopsy was 85.7 and
46.9 %, respectively (p = 0.067). For PFS, the 2-year
survival rate for patients with a complete resection and
those with a subtotal resection/biopsy was 85.7 and
50.0 %, respectively (p = 0.084). Gender (OS: p = 0.42;
PFS: p = 0.45), tumor size (\5 vs. C5 cm; OS: p = 0.49;
PFS: p = 0.37), the administration of concomitant che-
motherapy (yes vs. no; OS: p = 0.35; PFS: p = 0.43) and
age of the patient (\12 vs. C12 months; OS p = 0.79;
PFS: p = 0.70) was not significant for both OS or PFS.
PT was well tolerated. PT was delivered without any
interruption for all patients. Only 2 (13 %) patients had a
decreased performance status of WHO 2 after PT. Bone
marrow grade 1 and 2 acute toxicity was observed in 11
and 2 children, respectively. Alopecia was observed in all
children. All but one child had grade 1–2 erythema. No
grade C3 acute toxicity was observed. Two (13 %) chil-
dren presented with late toxicity (grade 1 and 4 motor
dysfunction, respectively). In one of these patients, radio-
necrosis was observed. This young girl of 22.8 months of
age at the time of diagnosis presented with tetra-paresis and
a radio-necrosis in the mesial aspect of the temporal lobe
and brainstem. She is currently alive 43.5 months after
PBS. In this series, the estimated 2-year TFS was 90 % (CI
95 % 71.4–100).
All parents filled the PedsQoL proxy evaluation at
baseline (E1). A second evaluation (E2) was obtained at
2 months of follow-up for 9 (60 %) children in at least one
QoL-metric. The results are detailed in Table 3. Only
minimal changes in Physical and Emotion function, as well
as in the Summary scores, were observed. Noteworthy,
slightly higher negative variations in Social function were
observed. Using PedsQoL proxy, these results suggest that
PT did not negatively impact the overall QoL of these
ATRT patients treated with PT.
Discussion
We report outcomes in a cohort of 15 children treated with
PT for ATRT and to the best of our knowledge, the present
series is the only series ever published on this tumor entity
using PT and PBS. Protons have a depth-dose distribution
that is characterized by a narrow Bragg peak and a sharp
distal fall-off beyond this range. PBS, as opposed to pas-
sive scattering, enables to increase the dose conformity of
proton radiation, proximal to the target volume. As such,
the brain-integral dose and the radiation administered to
CNS critical structures in vicinity of the target may be
decreased with PBS, which could lead in a decrease of
radiation-induced toxicity. A previous series reported on
the outcome of 10 ATRT patients treated with passive
scattering PT [9]. As such, PT have been successfully
administered to children with brain tumors [10, 11], for
whom the young age during treatment and the proximity of
critical structures make protons an exciting radiation
Fig. 2 Progression-free survival in 15 patients with supra- (n = 6)
and infratentorial (n = 9) ATRT treated with proton therapy
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modality. Due to the small number of proton facilities
worldwide, the poor prognosis associated with this tumor
entity and the higher costs associated with protons, PT is
usually not administered to these young children. Given the
increased number of constructed proton facilities and the
improved overall prognosis of these patients, it is of par-
amount importance that this treatment modality should be
indeed considered for these patients. With an estimated
2 year-survival of 66.0 % of patients in our series, a sub-
stantial number of ATRT patients could benefit of this
highly conformal treatment with no serious toxicity or
decreased in QoL. As for the treatment costs, a number of
cost-effectiveness analyses have suggested that PT for
brain tumors in children were associated with lower costs
and higher quality-adjusted life years [12, 13]. Some series,
using a Markov model, have even shown that protons could
be cost-saving for medulloblastoma [14].
The higher frequency of ATRT in infants complicates
substantially therapy due to the customary avoidance of RT
in some groups in this age category [15]. Radiation therapy
remains however one of the most important treatment
modality for this challenging tumor occurring in very
young children. In the Korean study, tumor relapse or
progression during induction chemotherapy was seen in the
majority (56 %) of patients treated with a HD chemother-
apy regimen [16]. The same percentage (55 %) of tumor
progression or relapse during chemotherapy was observed
in the St Jude series [17]. Two studies have shown undis-
putedly the importance of RT. A retrospective review of 31
patients followed up at St. Jude Children’s Research Hos-
pital suggested that children who received chemotherapy
and radiotherapy had a better outcome [18]. Likewise, the
results of the baby Pediatric Oncology Group 2 study,
addressing the efficacy of HD chemotherapy to avoid or
delay radiation in young children, showed that all 36
ATRT patients included in this protocol ultimately died of
their disease. The median unreported OS was only
6.7 months [19].
The timing of RT has been even less studied in the
available literature. Two important series have however
been published in Taiwan and in the US. Chen et al.
reported retrospectively on 17 patients treated with che-
motherapy and mainly CSI [20]. The median OS was
17 months and multivariate analysis revealed a significant
relationship between overall survival and the time interval
between surgery and radiotherapy initiation (p = 0.031).
Moreover, the time to radiation completion (p = 0.047)
was also significantly associated with OS. Likewise, the St.
Jude group reported on 31 patients (median age 2.3 years)
treated with focal RT or with the addition of CSI [17].
Using a Cox regression model, the authors have shown that
children receiving delayed ([1 month postoperatively) RT
were more likely to experience local failure (hazard ratio
1.23, p = 0.007) than those who received immediate
postoperative RT. As such, it is of critical importance to
have RT timely delivered after the initial surgery.
The pathogenesis of ATRT is still poorly understood
and molecular markers for risk-adapted patient stratifica-
tion are not available. As such, we rely on a number of
crude clinical prognosticators. The prognostic impact of
ATRT localization is debated. This clinical prognostic
factor has not been analyzed in numerous series [16, 17, 20,
21]. In a tumor registry US series, 8 (58 %) of the long
term survivors had supratentorial tumors, but no formal
analysis was made for this parameter [1]. In another pop-
ulation-based tumor registry Austrian study, tumor locali-
zation was not associated with OS (p = 0.49) [3]. The
same finding was observed in a recently published large
retrospective Canadian series [22] and in a meta-analysis of
observational studies performed by Athale et al. [4].. In the
HIT series however, overall survival was significantly
higher (p = 0.003) in patients with supratentorial tumor
localization (3 year OS: 38 ± 10 %) compared to patients
with infratentorial tumors (3 year OS: 5 ± 4 %) [23].
Conversely, the calculated median OS for patients with
supratentorial ATRTs was 24 months and significantly
(p = 0.04) shorter than the survivorship of patients with
posterior fossa tumors (median OS not yet reached) in the
Dana-Farber study [15]. In our study, we also observed that
the survival rate of patients with posterior-fossa tumors was
better by a factor of approximately three when compared to
those with supratentorial tumors (p = 0.012). Possible
explanations for this finding include imbalances between
the two groups with respect to known and unknown base-
line prognostic factors, imbalances in the use of second
therapies if any, statistical chance or a real tumour locali-
zation difference.
Younger age is usually an adverse prognostic factor for
ATRT patients. In the HIT series, children younger than
the median age at diagnosis (15 months) had a lower event-
free survival (p = 0.044) and OS (p = 0.002) than older
children [23]. Likewise, in a retrospective analysis of 37
patients treated at St Jude, the estimated 2-year OS was
17 ± 8 and 89 ± 11 % (p = 0.009) for children younger
and older than 36 months, respectively. The corresponding
value for the event-free survival was 11 ± 6 and
78 ± 14 % and this difference was highly significant
(p = 0.0001) [18]. A poorer outcome was also observed in
children\12 months of age in the Canadian retrospective
analysis but this trend did not reach statistical significance
(p = 0.06) [22]. Age was however not a significant factor
(p = 0.4) in the Dana-Farber series [15], nor was it a
prognosticator in the aforementioned tumor registry Aus-
trian study [3] and meta-analysis series [4]. In our series,
we did not find that age was a significant prognostic factor.
Younger ATRT patients in our series had usually a
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supratentorial tumor and older patients an infratentorial
ATRT.
We have observed that the OS for the 7 patients who had
complete resection was 31.7 months (range 12.4–69.2),
compared to the OS of 21.4 months (range 9.7–59.3) for
the subset with a partial resection/biopsy (p = 0.067). The
same statistical trend for event-free survival was observed
in the HIT series [23]. Likewise, the extent of the initial
tumor resection was correlated with OS in the early and
recently published St Jude series but not significantly so
[17, 18]. This is in line with the Dana–Farber series which
reported a 2-year OS of 91 ± 9 % for patients who
achieved a gross total resection, whereas the reported
median OS of less than gross totally resected patient was
18 months (p = 0.004) [15]. In the Austrian tumor registry
study, extent of resection was also significantly associated
with improved survival (p = 0.013) [3]. As a result of the
published data, we would strongly recommend that an
aggressive surgical strategy be undertaken, including sec-
ond-look surgery, to best achieve gross total resection.
This is also the first analysis to report the QoL outcome
of children with ATRTs after PT. Pediatric malignant brain
tumors are often associated with physical, cognitive, psy-
chological and behavioral difficulties that may affect sub-
stantially the QoL of children and their families. In this
study, we analyzed the parental report of QoL in children
with ATRT. Parent-proxy reported QoL for children with
various chronic CNS disease, not limited to but including
cerebral palsy [24], obsessive–compulsive [25] and atten-
tion-deficit hyperactivity disorders [26] have been suc-
cessful in detecting children’s impairment with these
conditions. For children with cancer, this proxy-reporting
has not been fully assessed and validated. As such, great
care should be taken not to over-interpret these data in this
small cohort of very young children with a rare brain
tumor. Notwithstanding the lack of definite proof of
validity in parental report for this challenging tumor, our
data suggests that PT may not have a detrimental effect on
the QoL of these patients. The increased mean scores of 3/5
domains after therapy may suggest an improvement of
QoL, when compared to baseline scores (Table 3).
There were several limitations of our study. First, the
study design was retrospective in nature and thus lacked
complete data for certain variables such as cumulative
chemotherapy dose. Second, the small sample size of 15
patients limited the statistical power to detect associations
between tumour progression and some of the clinical fac-
tors examined. A third limitation is the possible underre-
porting of treatment-related toxicity. Although every
patient was jointly followed up at 2–3-monthly intervals by
both their treating medical and radiation oncologist, it is
still possible, albeit unlikely, that asymptomatic patients
may have had radiographic evidence of radiation-induced
toxicity that went unreported, especially in a retrospective
analysis. Finally, no central review of pathology was per-
formed for the analysis, but the loss of INI-1 expression for
all patients (Table 1) in tumours that had all histological
characteristics of ATRT mitigates somewhat this
disclaimer.
Conclusions
Our data suggests that PBS PT is an effective treatment for
young children with ATRT. After PT, with or without
concomitant chemotherapy, two third of the patients sur-
vived [2 years. The acute toxicity was limited and our
prospective parental-proxy reporting data do not suggest a
decrease of QoL of these very young patients. Late toxicity
was unusual. Supratentorial tumor localization, occurring
usually in very young patients, was a negative prognostic
factor in our series.
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